Ryvu Therapeutics (STU:9Y4) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9Y4 Ryvu Therapeutics SA STU:9Y4
68 GF Score
Price €3.31
GF Value €10.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:9Y4 vs VRTX, REGN, RVMD: Short Percentage of Float Comparison

For the Biotechnology subindustry, Ryvu Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ryvu Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Short Percentage of Float falls into.


STU:9Y4
68GF Score
Ryvu Therapeutics SA STU:9Y4
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ryvu Therapeutics (STU:9Y4) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of €3.31 is trading 67.6% below its estimated GF Value™ of €10.19. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for STU:9Y4:

  • Short Percentage of Float:
  • GF Value™: €10.19 vs. price of €3.31 (67.6% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the STU:9Y4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
68GF Score

Get the complete analysis for STU:9Y4

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.31
Price
€10.19
GF Value